A Neck Surgery Claiming to Reverse Alzheimer's Has Scientists Divided

A Viral Surgery Sparks Global Debate

The video was impossible to ignore. An 84-year-old dementia patient, first shown slumped and unresponsive in a hospital bed, appears alert, walking, and talking just six months after an experimental neck surgery. That jaw-dropping footage sparked "a frenzy of this surgery being performed left and right," according to Nature. And with it came a question that has gripped researchers, families, and clinicians around the world: could a relatively simple plumbing fix in the neck actually reverse Alzheimer's disease?

The procedure is called deep cervical lymphatic-venous anastomosis, or dcLVA. As the brain's fluid drainage systems become sluggish with age, troublemakers such as amyloid and tau aggregates start to build up — and to flush out that disease-causing detritus, neurosurgeons in China developed a controversial procedure that essentially opens the lymphatic tap, conjoining lymphatic vessels exiting the brain with veins in the neck to improve lymphatic outflow. The theory is elegant: if toxic proteins can't drain properly, help them drain better.

The Science Behind the Idea

The rationale draws on relatively recent findings about meningeal lymphatic vessels, which drain cerebrospinal fluid into the deep cervical lymph nodes as part of the brain's broader glymphatic clearance system — the pathway thought to help clear amyloid-beta and tau aggregates implicated in Alzheimer's disease. The theory behind dcLVA is that age-related sluggishness in this drainage route contributes to protein buildup, and that surgically rerouting lymphatic flow into the venous system eases outflow from the brain.

It's a compelling hypothesis — but a hypothesis is all it remains for now. The mechanism is theoretical; it has not been established that the surgery produces the drainage improvement it is premised on, let alone that improved drainage changes the course of Alzheimer's disease. Critics point out that viral patient videos, however moving, are not clinical evidence. Spontaneous fluctuations in dementia symptoms are well-documented, and without controlled trials, there's no way to know whether the surgery — or something else entirely — is responsible for any improvement.

China's Crackdown and a Pioneer's Arrest

More than 2,000 people in China underwent the experimental surgery before authorities intervened. In July 2025, China's National Health Commission banned routine clinical use of dcLVA, citing a lack of robust clinical evidence. The fallout was swift and dramatic. The procedure's pioneer — microsurgeon Qingping Xie, president of Qiushi Hospital in Hangzhou — was detained by Chinese authorities in December for undisclosed reasons.

The ban didn't kill the science, though. It redirected it. Studies utilizing the technique are now underway around the world, with more than 20 clinical trials active in China alone. The CLEAN-AD Registry plans approximately 814 patients across about 40 centers, with follow-up to 24 months and a broad set of clinical, imaging, fluid-biomarker, caregiver, and safety measures. Researchers are now trying to do what was never done before the procedure went viral: rigorously test it.

What Comes Next

High-quality, multicenter, randomized controlled trials with long-term follow-up are considered mandatory to validate efficacy, confirm safety, clarify mechanisms, and standardize surgical protocols. Those trials should use sham surgery controls, blinded outcome assessments, and objective biomarkers as primary endpoints, rather than subjective cognitive scales alone. That's a high bar — and exactly the right one for a disease that has broken so many hearts and dashed so many promising treatments over the decades.

For the millions of families living with Alzheimer's, the dcLVA story captures a painful tension: the desperate need for hope versus the scientific discipline required to turn hope into something real. The surgery may ultimately prove to be a breakthrough, a dead end, or something in between. What's clear is that the world is now paying attention — and the trials now underway will, at last, start delivering answers built on evidence rather than emotion.